Overview
CJC-1295 (No DAC) + Ipamorelin Peptide Blend is a streamlined research formulation designed to investigate coordinated growth hormone signaling pathways within controlled laboratory environments. By combining a GHRH analog with a ghrelin receptor agonist, this blend enables investigational work involving pulsatile GH signaling models, endocrine pathway interaction, and peptide-mediated signaling coordination.
This blend is supplied strictly for laboratory and investigational research purposes.
Compound Breakdown
Each peptide within the blend contributes a distinct investigational signaling role:
CJC-1295 (No DAC) — studied as a growth hormone-releasing hormone (GHRH) analog involved in pulsatile GH signaling pathway investigations
Ipamorelin — investigated as a selective ghrelin receptor agonist studied for growth hormone signaling and receptor-specific peptide interaction models
Together, these peptides support investigation into coordinated endocrine signaling frameworks and layered peptide-mediated GH pathway research systems.
Research Context
Research investigations involving CJC-1295 (No DAC) + Ipamorelin Peptide Blend commonly explore:
• Pulsatile growth hormone signaling frameworks
• GHRH and ghrelin receptor pathway interaction models
• Coordinated endocrine peptide signaling investigations
• Multi-pathway peptide signaling systems
• Comparative GH-axis peptide research models
These investigations remain limited to controlled laboratory environments and do not imply clinical or therapeutic outcomes.
Related Categories
Researchers evaluating CJC-1295 (No DAC) + Ipamorelin Peptide Blend commonly compare it with CJC-1295 (No DAC) Peptide, Ipamorelin Peptide, Tesamorelin Peptide, and broader endocrine-focused research formulations such as the GH Release Bundle and Hormone Support Bundle.
Testing & Verification
Each batch supplied by Not Labs undergoes independent analytical testing to verify compound identity, purity, and integrity. Batch-specific Certificates of Analysis (COAs) are provided for transparency and research verification purposes.
Where applicable, purity specifications (≥99%) are indicated on product labeling and corresponding COA documentation.
Research FAQ
What research frameworks commonly investigate CJC-1295 (No DAC) and Ipamorelin together?
CJC-1295 (No DAC) and Ipamorelin are commonly investigated together within laboratory models involving pulsatile growth hormone signaling, endocrine pathway coordination, and peptide-mediated receptor interaction frameworks.
How does CJC-1295 (No DAC) differ mechanistically from Ipamorelin in research settings?
CJC-1295 (No DAC) is investigated as a GHRH analog associated with upstream GH signaling pathways, whereas Ipamorelin is studied as a selective ghrelin receptor agonist involved in receptor-mediated GH signaling interaction models.
Why are GHRH analogs and ghrelin receptor agonists studied together?
Researchers investigate these peptide classes together to evaluate coordinated signaling behavior across multiple GH-axis pathways within controlled investigational systems.
What distinguishes CJC-1295 (No DAC) from DAC-modified variants in laboratory research?
CJC-1295 (No DAC) is commonly investigated in pulsatile signaling models due to its shorter activity profile relative to DAC-modified formulations studied in extended-duration pathway investigations.
Is analytical verification documentation available for this blend?
Yes. Batch-specific analytical verification documentation is available and includes identity and purity-related testing associated with the corresponding production batch.
What form is this product supplied in?
This product is supplied in a lyophilized peptide format intended for laboratory handling, storage, and investigational research workflows.
Scientific References
See the individual product pages for primary citations and research models:
